Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
-       Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers -       IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients with recurrent glioblastoma -       Results further support development of
View HTML
Toggle Summary Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
-Expanding Controlled IL-12 platform to explore additional tumor types -Cash runway extended to 2Q 2019 with changes to Controlled IL-12 development plans -ASCO poster to detail IL-12 data in breast cancer, glioblastoma, highlight potential for combination with checkpoint inhibitors
View HTML
Toggle Summary Ziopharm Oncology to Announce First Quarter 2018 Financial Results, Host Conference Call May 10
BOSTON , May 02, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, May 10 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended
View HTML
Toggle Summary Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Company to host conference call today at 4:30 p.m. ET
View HTML
Toggle Summary Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1
BOSTON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, March 1, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and
View HTML
Toggle Summary Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond
Human CAR+ T cells with membrane-bound IL-15 manufactured in less than two days exhibited anti-tumor activity and persistence in pre-clinical studies
View HTML
Toggle Summary Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance
BOSTON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no developments at the Company that would be the cause of the recent volatility and decline in
View HTML
Toggle Summary Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference
- Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO ® (nivolumab) - - Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for multiple oncology targets - BOSTON, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc.
View HTML
Toggle Summary ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 10 a.m. PST.
View HTML
Toggle Summary ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting
— Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty -modified CD19-specific CAR + T cells — — Point-of-care CD19-specific CAR + T cells co-expressing mbIL15 with control switch show sustained persistence, anti-tumor effect in preclinical
View HTML